AB Science

Focus: AB Science is a French-based biotech company focused on small molecule development across oncology, neurology, immunology, and respiratory indications. The company operates as a mid-cap biotech with a diversified pipeline in clinical development.

Oncology Neurology Immunology Unknown

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About AB Science

AI assessmentNot Hiring

No open roles listed right now. Follow AB Science to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Study characteristics of adolescents affected by dental caries

Caries,Dental

N/A

Clinical Trials (1)

NCT05935813Caries in Adolescents (Karies Hos Ungdom)

N/A

Help build intelligence for AB Science

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead role in masitinib Phase 3 program with 37 active trials, offering substantial clinical development experience in a late-stage asset
Geographically anchored in Paris with European regulatory expertise in a growing biotech hub
Diverse therapeutic portfolio spanning oncology, neurology, and immunology provides exposure to multiple disease areas

Watch Out For

No disclosed revenue or profitability data suggests early-stage commercial status or private structure with limited financial transparency
Currently hiring only 5 roles in Clinical department, indicating minimal near-term growth or expansion plans
Pipeline shows early-stage diversity (5 Phase 1 programs) rather than depth, with significant clinical risk across most assets

Generated by Claude from AB Science's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Multiple Sclerosis

N/A

14C-AB1010

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05200169Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

Phase 1

GoodIdea

Healthy Volunteers

Phase 1